Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: Trends Pharmacol Sci. 2016 Oct 3;38(1):55–66. doi: 10.1016/j.tips.2016.09.006

Figure 3.

Figure 3

The rs1051730–rs16969968 genetic variant in the nicotinic receptor does not influence smoking cessation outcomes on NRT.

Effect sizes (odds ratios) from four clinical studies [61, 79–81] comprising NRT treatment arms show the likelihood of successful smoking cessation at end-of-treatment for smokers with the rs1051730-rs16969968 risk allele (rs1051730 T allele or rs16969968 A allele) relative to smokers with the rs1051730-rs16969968 reference allele (rs1051730 C or rs16969968 G allele). This figure is adapted from a meta-analysis performed by Leung et al, 2015 [7]. The overall effect size from the meta-analyzed data is also depicted. Results were generated from additive genetic models adjusting for age and sex. No significant heterogeneity was present in the meta-analysis (I2=50.6%; P=0.07). The dashed vertical line represents the overall effect size, which was 0.97. Abbreviations: PiP, Patch in Practice study; CI, confidence interval